Showing 321 - 340 results of 105,443 for search '(( 10 ((ng decrease) OR (we decrease)) ) OR ( 5 ((a decrease) OR (nn decrease)) ))', query time: 1.17s Refine Results
  1. 321
  2. 322
  3. 323

    Evaluation index results for the JS-10 phantom. by Masakazu Tsujimoto (22339504)

    Published 2025
    “…At ≥50 s/view, variation in the maximum and mean SUVs decreased, with the RSE remaining below 5%. In conclusion, accurate SUV measurement with ¹²³I-MIBG requires an acquisition time of ≥50 s/view, an SI product of approximately 120, and a Gaussian filter of 10 − 12 mm. …”
  4. 324

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  5. 325
  6. 326

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”
  7. 327

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”
  8. 328

    Image_1_Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons.... by Yize Li (471459)

    Published 2022
    “…Artesunate normalized paclitaxel-related expression changes in DRG mGluR5, NR1, and GluA2, as well as six paclitaxel related neuroinflammation markers. …”
  9. 329
  10. 330

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  11. 331

    Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  12. 332
  13. 333

    Table_1_A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit.pdf by Yajun Jing (11711139)

    Published 2022
    “…In multivariable analysis, even after excluding the confounding factors, such as age, APECHII score, pre-ECMO lactate, and incidence of CRRT during ECMO, the intervention bundle still can decrease the mortality independently, which also remained true in the statistical analysis of V-V and V-A ECMO separately. …”
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339

    Supplementary Material for: Kidney and cardiovascular outcomes in older population with mildly to moderately decreased kidney function - A nationwide cohort study by Jeon J. (10323467)

    Published 2024
    “…Introduction: Although the prevalence of chronic kidney disease (CKD) is increasing in the aging population, the clinical relevance of the CKD definition (glomerular filtration rate [GFR] < 60 ml/min/1.73 m2) in older populations remains debatable. We investigated the clinical outcomes in older populations with mildly to moderately decreased GFR (45–59 ml/min/1.73 m2, CKD stage 3A). …”
  20. 340